Drugs / ACETYLCYSTEINE ZIDRIMER
ACETYLCYSTEINE ZIDRIMER
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04321980 | Mar → May 2020 | — | Orpheris, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03500627 | Mar → Jul 2018 | — | Orpheris, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04458298 | Aug 2020 → Aug 2022 | COVID-19 | Ashvattha Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACETYLCYSTEINE ZIDRIMER | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315034 ↗ |
| Known as | Dendrimer N-acetyl-cysteine | “A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous...” NCT03500627 ↗2“A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients” NCT04458298 ↗ “OP-101 (Dendrimer N-acetyl-cysteine)” NCT04321980 ↗ |
| Known as | OP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04321980 ↗ |
| Modality | Small molecule | — CHEMBL5315034 ↗ |
| Route | Intravenous | “After Intravenous Administration” NCT03500627 ↗ |